Skip to main content
Wanbury Limited logo

Wanbury Limited — Investor Relations & Filings

Ticker · WANBURY ISIN · INE107F01022 LEI · 335800QB384KGMBID276 BSE.NS Manufacturing
Open in API
Filings indexed 916 across all filing types
Latest filing 2023-10-20 Regulatory Filings
Country IN India
Listing BSE.NS WANBURY

About Wanbury Limited

https://www.wanbury.com

Wanbury Limited specializes in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and finished formulations. The organization maintains a significant global presence, particularly as a leading producer of Metformin. Its product portfolio spans diverse therapeutic areas, including gynecology, orthopedics, hematinics, and anti-diabetics. The company operates manufacturing facilities compliant with international regulatory standards, including the USFDA. Wanbury focuses on providing medicinal solutions through integrated research and development capabilities and large-scale production infrastructure, serving both domestic and international markets with a range of specialty products.

Recent filings

Filing Released Lang Actions
This is with reference to the above mentioned subject, we, Wanbury Limited (the "Company") would like to inform you that the Board of Directors of the Company at its meeting held today ....
Regulatory Filings
2023-10-20 English
Outcome of Board Meeting
Regulatory Filings
2023-10-20 English
Board Meeting — WANBURY LIMITED has informed the Exchange about Board Meeting to be held on 20-Oct-2023 to consider Fund raising.
Regulatory Filings
2023-10-17 English
WANBURY LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/10/2023 ,inter alia, to consider and approve This communication is in continuation ....
Regulatory Filings
2023-10-17 English
Board Meeting — Fund Raising
Regulatory Filings Classification · 100% confidence The document text is extremely short (625 characters) and contains no substantive content related to financial performance, management changes, or any specific report. It appears to be a digital signature block with no report or announcement content. There are no references to any report type, fiscal period, or regulatory body. Given the lack of content and the nature of the text, this document does not represent a financial report or announcement but rather a regulatory or administrative filing. According to the rules, such minimal content with no report details defaults to Regulatory Filings (RNS).
2023-10-17 English
Board Meeting — WANBURY LIMITED has informed the Exchange about Board Meeting to be held on 20-Oct-2023 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half…
Regulatory Filings
2023-10-12 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.